Search Results

11 - 20 of 112 items :

  • "acute lymphoblastic leukaemia" x
Clear All
Acute Lymphocytic Leukemia in Adults. Pathologic Features and Prognosis

, LAZARUS HM, FRANKLIN IM, LITZOW MR, CIOBANU N, PRENTICE HG, DURRANT J, TALLMAN MS & GOLDSTONE AH. Induction therapy for adults with acute lymphoblastic leukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106, 3760-3767. 5. JACOB M ROWE. Prognostic factors in adult acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 150, 389-405. 6. MOORMAN AV, CHILTON L, WILKINSON J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia

Open access
Adult B Lymphoblastic Leukemia with a Novel De Novo Chromosomal Translocation [Der(9)t(9;12)(p24;q12),-12]: A Case Report

review of literature. J Hematol Oncol. 2009; 2(1): 26-31. 3. Atlas of Genetics and Cytogenetics in Oncology and Haematology online, 1998 (http://atlasgeneticsoncol ogy.org/). 4. Bargetzi MJ, Mühlematter D, Tichelli A, Jotterand M, Wernli M. Dicentric translocation (9;12) presenting as refractory Philadelphia chromosomepositive acute B-cell lymphoblastic leukemia. Cancer Genet Cytogenet. 1999; 113(1): 90-92. 5. D’Angelo G, Hotz AM, Todeschin P. Acute lymphoblastic leukemia with hypereosinophilia and 9p21 deletion: case

Open access
Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection

References 1. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukaemia and its relationship to other prognostic factors: A Children’s Oncology Group study. Blood 2008;111:5477-85. 2. Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012;19(4):313-8. 3. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acute lymphoblastic leukemia in children. Treatment planning via minimal

Open access
Multidrug resistance gene 1 polymorphisms in pediatric patients with leukemia at a national referral hospital in Indonesia

[ 2 ]. The most common malignancy in the pediatric population worldwide is acute lymphoblastic leukemia (ALL). ALL is a heterogeneous group of leukemias that result from the clonal proliferation of cancerous lymphoblasts in bone marrow, and in secondary lymphoid organs. Children 1–10 years old are at particular risk of developing ALL. The overall cure rate is approximately 80% [ 3 ]. The Indonesian Paediatric Oncology Foundation stated that 2%-3% cancer cases in Indonesia occur in children [ 4 ]. Based on Cipto Mangunkusumo Hospital data from 2000-2006, there were

Open access
Evaluation of Gingival Conditions and Saliva TNF-α Concentration in Children with Acute Lymphoblastic Leukemia

acute lymphoblastic leukemia in Northern Ireland. Community Dent Oral Epidemiol. 1993;21(5):309-12. 17. Kinirons MJ, Fleming P, Boyd D. Dental caries experience of children in remission from acute lymphoblastic leukaemia in relation to the duration of treatment and the period of time in remission. Int J Paediatr Dent. 1995;5(3):169-72. 18. Sonis AL, Waber DP, Sallan S, Tarbell NJ. The oral health of long-term survivors of acute lymphoblastic lekaemia: a comparisonof three treatment modalites. Oral Oncol Eur J Cancer. 1995;31B(4):250-2. 19. Avşar A, Elli M, Darka

Open access
Evaluation of the combined effects of doxorubicin and bortezomib on the human acute lymphoblastic leukemia cell line

Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2017;15:230-69. 10. https://clinicaltrials.gov/ct2/results?cond=&term=bortezomib%2C+doxorubicin&cntry=&state=&city=&dist= open access: 01.09.2018 11. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal . 2017;7:e577. 12. ClinicalTrials.gov Identifier: NCT00440726 13. https://clinicaltrials.gov/ct2/show/NCT00440726?term=bortezomib%2C+doxorubicin&cond=ALL%2C+Childhood&rank=1 open access: 01.09.2018 14

Open access
The impact of immunological and biomolecular investigations on the outcome of children with acute lymphoblastic leukemia - experience of IIIrd Paediatric Clinic Timisoara

References 1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013 Jun;381(9881):1943-55. DOI: 10.1016/S0140-6736(12)62187-4 2. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. Dtsch Arzteblatt Int. 2012 Oct;109(40):652-8. 3. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009 Jan;144(2):147-56. DOI: 10.1111/j.1365-2141.2008.07417.x

Open access
Disseminated Fusarium Infections in Acute Lymphoblastic Leukemia

Abstract

Fusarium is a ubiquitous fungal species found in soil and water. While fusarium can cause localized infection in healthy individuals, it most commonly affects those with compromised immune systems, particularly those with prolonged neutropenia. The morality rate of systemic infection approaches one-hundred percent. Here we present two cases of disseminated fusarium infection in two patients with acute lymphoblastic leukemia (ALL) along with review of literatures regarding prophylaxis and treatment.

Open access
Pharmacogenomic markers of glucocorticoid response in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemia

Introduction Acute lymphoblastic leukemia (ALL) is the most common hematological and overall malignancy in pediatrics, accounting for around 30% of all childhood cancers and around 80% of all childhood leukemias. It is one of the pediatric malignancies with the highest cure rate, exceeding 80%, when treated with standardized protocols like the European standard, the Berlin-Frankfurt-Munster (BFM) protocol. 1 , 2 , 3 However, there is still more than 10% of patients with unfavorable outcome. The treatment of childhood ALL is based on risk stratification

Open access
Expression pattern of long non-coding RNA growth arrest-specific 5 in the remission induction therapy in childhood acute lymphoblastic leukemia

Introduction Among pediatric malignancies, acute lymphoblastic leukemia (ALL) is the most common hematological and overall malignancy, contributing to 30% of diagnosed cancers and around 80% of all pediatric leukemias. Pediatric ALL is a malignancy with one of the highest cure rates, achieved by treating the patients with the internationally recognised treatment protocols like the Berlin-Frankfurt-Munster (BFM) protocol ( 1 , 2 , 3 ). Risk stratification of ALL is para mount in choosing the effective treatment strategy. Hence, risk stratification is already

Open access